Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice
Histone deacetylase 9 (HDAC9) is expressed in B cells, and its overexpression has been observed in B-lymphoproliferative disorders, including B-cell non-Hodgkin lymphoma (B-NHL). We examined HDAC9 protein expression and copy number alterations in primary B-NHL samples, identifying high HDAC9 express...
Main Authors: | Veronica S. Gil, Govind Bhagat, Louise Howell, Jiyuan Zhang, Chae H. Kim, Sven Stengel, Francisco Vega, Arthur Zelent, Kevin Petrie |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2016-12-01
|
Series: | Disease Models & Mechanisms |
Subjects: | |
Online Access: | http://dmm.biologists.org/content/9/12/1483 |
Similar Items
-
Recent Update of HDAC Inhibitors in Lymphoma
by: I-Chung Chen, et al.
Published: (2020-09-01) -
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
by: Maria Cosenza, et al.
Published: (2018-08-01) -
Mouse Models of Germinal Center Derived B-Cell Lymphomas
by: Stefanie N. Meyer, et al.
Published: (2021-08-01) -
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model
by: Chiranjeevi Sandi, et al.
Published: (2011-06-01) -
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
by: Xiaoguang Wang, et al.
Published: (2020-03-01)